1:00 PM ET | noon CT | 11:00 AM MT | 10:00 AM PT
Epic Bio, a San Francisco based therapeutics company, is developing a gene therapy medicine specifically for FSHD patients. The new product, termed EPI-321, leverages a CRISPR-based platform to precisely find and fix the specific issue in the genome that causes FSHD. It works by restoring a process called methylation to repair the root cause of the disease without altering the DNA sequence. EPI-321 is an AAV-based gene therapy product delivered one time via intravenous infusion.
Our speaker is Alexandra Collin de l’Hortet, PhD, Head of Therapeutics at Epic Bio. Dr. Collin de l’Hortet leads the efforts to transform the powerful technology platform of epigenomic engineering into a new class of gene therapy medicines. She has over ten years of experience managing biomedical research. Prior to joining Epic Bio, she worked at Krystal Biotech, where she provided scientific and strategic leadership to the product development team, and managed several gene therapy programs from discovery through to Phase III.
Plans for the first clinical trial in FSHD will be discussed.